These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28407755)

  • 1. Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis.
    Wheat CL; Ko CW; Clark-Snustad K; Grembowski D; Thornton TA; Devine B
    BMC Gastroenterol; 2017 Apr; 17(1):52. PubMed ID: 28407755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
    Bonovas S; Fiorino G; Allocca M; Lytras T; Nikolopoulos GK; Peyrin-Biroulet L; Danese S
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1385-1397.e10. PubMed ID: 27189910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis.
    Gubatan J; Nielsen OH; Levitte S; Juhl CB; Maxwell C; Streett SE; Habtezion A
    Am J Gastroenterol; 2021 Feb; 116(2):243-253. PubMed ID: 33110017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
    Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease.
    Piovani D; Danese S; Peyrin-Biroulet L; Nikolopoulos GK; Bonovas S
    Aliment Pharmacol Ther; 2020 May; 51(9):820-830. PubMed ID: 32170782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis.
    Chen L; Xu CJ; Wu W; Ding BJ; Liu ZJ
    J Dig Dis; 2021 Jul; 22(7):408-418. PubMed ID: 34048629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
    Borren NZ; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease.
    Wilson DC; Thomas AG; Croft NM; Newby E; Akobeng AK; Sawczenko A; Fell JM; Murphy MS; Beattie RM; Sandhu BK; Mitton SG; ; Casson D; Elawad M; Heuschkel R; Jenkins H; Johnson T; Macdonald S; Murch SH
    J Pediatr Gastroenterol Nutr; 2010 Feb; 50 Suppl 1():S14-34. PubMed ID: 20081542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Solitano V; Facciorusso A; Jess T; Ma C; Hassan C; Repici A; Jairath V; Armuzzi A; Singh S
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):907-921.e2. PubMed ID: 35944832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
    Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis.
    Ribaldone DG; Fagoonee S; Astegiano M; De Angelis C; Smedile A; Caviglia GP; Petrini E; Greco A; Pellicano R
    Pain Physician; 2015 Nov; 18(6):599-607. PubMed ID: 26606012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid but not Biological Therapy Elevates the risk of Venous Thromboembolic Events in Inflammatory Bowel Disease: A Meta-Analysis.
    Sarlos P; Szemes K; Hegyi P; Garami A; Szabo I; Illes A; Solymar M; Petervari E; Vincze A; Par G; Bajor J; Czimmer J; Huszar O; Varju P; Farkas N
    J Crohns Colitis; 2018 Mar; 12(4):489-498. PubMed ID: 29220427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.
    Esse S; Mason KJ; Green AC; Warren RB
    JAMA Dermatol; 2020 Jul; 156(7):787-794. PubMed ID: 32432649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of sex and socioeconomic status on the likelihood of surgery, hospitalization, and use of medications in inflammatory bowel disease: a systematic review and meta-analysis.
    Rasmussen NF; Moos C; Gregersen LHK; Hikmat Z; Andersen V; Green A; Jess T; Madsen GI; Pedersen AK; Petersen SR; Kjeldsen LJ
    Syst Rev; 2024 Jun; 13(1):164. PubMed ID: 38915086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Peyrin-Biroulet L; Van Assche G; Gómez-Ulloa D; García-Álvarez L; Lara N; Black CM; Kachroo S
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):25-36.e27. PubMed ID: 27392760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.